内容紹介
Summary
Background: The neutrophil lymphocyte ratio is reported to be a poor prognostic factor in each carcinoma, and the possibility of predicting the therapeutic effect of chemotherapy, for example, is being studied. In this study, we measured the NLR before and after administration of eribulin and the NLR before and after the final administration in breast cancer patients and examined the relationship with the therapeutic effect. Methods: Eleven primary breast cancer patients were examined after eribulin was administered; PD was confirmed eventually, and administration was discontinued. The NLR was determined before the first administration of eribulin and 7 days after the administration; the NLR before the final administration and after the last administration were each tested with p<0.05 as the significance level and using the t test. Results: The average value of NLR before initial administration was 4.07±2.11, and the average value after 7 days of administration was 2.47±1.97. The NLR before initial administration tended to be higher, and a significant difference was observed(p<0.05). The average NLR value before the final administration was 4.02±2.04, and the average value of the NLR after the final administration was 3.19±1.76, showing no significant difference(p=0.27, NS).
要旨
好中球・リンパ球比(neutrophil lymphocyte ratio: NLR)は化学療法の治療効果を予測し得る可能性についても検討されている。今回,乳癌においてeribulin投与前後のNLRと最終投与前後のNLRをそれぞれ測定し,治療効果との関連性について検討した。eribulinを投与した後,最終的にPDが確認され投与を中止した原発性乳癌11例を対象とした。これらについて,eribulin初回投与前と投与後7日目におけるNLR,最終投与前と最終投与後のNLRを,それぞれt検定を用いて検討した。初回投与前のNLR平均値は4.07±2.11,投与7日後の平均値は2.47±1.97であり,初回投与前のNLRのほうが高い傾向にあり,有意差を認めた(p<0.05)。最終投与前のNLR平均値は4.02±2.04,最終投与後NLR平均値は3.19±1.76であり,有意差を認めなかった(p=0.27,NS)。
目次
Background: The neutrophil lymphocyte ratio is reported to be a poor prognostic factor in each carcinoma, and the possibility of predicting the therapeutic effect of chemotherapy, for example, is being studied. In this study, we measured the NLR before and after administration of eribulin and the NLR before and after the final administration in breast cancer patients and examined the relationship with the therapeutic effect. Methods: Eleven primary breast cancer patients were examined after eribulin was administered; PD was confirmed eventually, and administration was discontinued. The NLR was determined before the first administration of eribulin and 7 days after the administration; the NLR before the final administration and after the last administration were each tested with p<0.05 as the significance level and using the t test. Results: The average value of NLR before initial administration was 4.07±2.11, and the average value after 7 days of administration was 2.47±1.97. The NLR before initial administration tended to be higher, and a significant difference was observed(p<0.05). The average NLR value before the final administration was 4.02±2.04, and the average value of the NLR after the final administration was 3.19±1.76, showing no significant difference(p=0.27, NS).
要旨
好中球・リンパ球比(neutrophil lymphocyte ratio: NLR)は化学療法の治療効果を予測し得る可能性についても検討されている。今回,乳癌においてeribulin投与前後のNLRと最終投与前後のNLRをそれぞれ測定し,治療効果との関連性について検討した。eribulinを投与した後,最終的にPDが確認され投与を中止した原発性乳癌11例を対象とした。これらについて,eribulin初回投与前と投与後7日目におけるNLR,最終投与前と最終投与後のNLRを,それぞれt検定を用いて検討した。初回投与前のNLR平均値は4.07±2.11,投与7日後の平均値は2.47±1.97であり,初回投与前のNLRのほうが高い傾向にあり,有意差を認めた(p<0.05)。最終投与前のNLR平均値は4.02±2.04,最終投与後NLR平均値は3.19±1.76であり,有意差を認めなかった(p=0.27,NS)。